Melanoma | Dr. Tony Talebi discusses what is melanoma and treatment of stage 1-3 melanoma

Dr. Tony Talebi discusses what is melanoma and treatment of stage 1-3 melanoma with Dr Weber. For further information visit http://www.HemOnc101.com.

Dr. Talebi's practice, Miami Hematology and Oncology Associates is located at 151 NW 11th street, Suite W303. Homestead, Fl 33030. Tel 786-504-3084

What is melanoma and treatment of stage 1 to 3 melanoma


The incidence of melanoma is increasing. Based upon data obtained between 2004 and 2006, the lifetime probability of developing melanoma in the United States is estimated to be 1 in 37 for men and 1 in 56 for women. This risk is substantially greater than noted in 1985 and 1965, when the lifetime risks for both sexes combined were estimated to be 1 in 150 and 1 in 600, respectively.


In the United States, melanoma is the fifth leading cancer in men and the seventh in women.

Clinical and epidemiologic evidence demonstrates higher rates of melanoma in people with extensive or repeated intense exposure to sunlight. The majority of melanomas develop on sun-exposed skin, particularly in areas that are more susceptible to sunburn. Individuals with naturally dark skin or whose skin darkens easily upon sun exposure have lower rates of melanoma, supporting the concept that greater penetration of UV light into the skin results in a higher risk.

Ultraviolet B radiation (UV-B, wavelengths 290 to 320 nanometers) appears more closely associated with the development of melanoma than UV-A (wavelengths 320 to 400 nanometers). Melanomas tend to be associated with intense, intermittent sun exposure and sunburns and they frequently occur in areas exposed to the sun only sporadically (eg, the back in men, the legs in women).

Here, Dr. Tony Talebi discusses the general concept of what is melanoma and treatment of stage 1 to 3 melanoma with world renowned melanoma expert Dr. Jeff Weber, professor of medicine at the Moffitt Comprehensive Cancer Center. The discussion includes symptoms, cause, diagnosis, staging, surgery, IL-2, chemotherapy, ipulimumab (Yervoy), and BRAF-inhibitor vemurafenib (Zelforab) treatment of melanoma.

Dr. Jeff Weber Credentials:


Titles:

Director, Donald A. Adam Comprehensive Melanoma Research Center
Department/Program Affiliations:

Cutaneous Oncology
Immunology
Primary Address:

H. Lee Moffitt Cancer Center

Education & Training:

Fellow, National Cancer Institute, 1990 - Surgery Branch, Tumor Immunology
Fellow, National Cancer Institute, 1988 - Surgery Branch, Tumor Immunology
Fellow, National Cancer Institute, 1986 - Medicine Branch
Resident, University of California, 1983 - Medicine
Intern, University of California, 1981 - Medicine
MD, New York University Medical Center, 1980
PhD, Rockefeller University, 1979 - Molecular Cell Biology
General Board Certification / SubSpecialty:

Internal Medicine / Medical Oncology

• Category

  Familial Malignant Melanoma